| Sorafenib in advanced hepatocellular carcinoma JM Llovet, S Ricci, V Mazzaferro, P Hilgard, E Gane, JF Blanc, ... New England Journal of Medicine 359 (23), 378-390, 2008 | 14873 | 2008 |
| AASLD practice guideline MS J Bruix Hepatology 42 (5), 1208-1236, 0 | 7324* | |
| EASL clinical practice guidelines: management of hepatocellular carcinoma European Association For The Study Of The Liver Journal of hepatology 69 (1), 182-236, 2018 | 6173 | 2018 |
| Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference JR Jordi Bruix*, Morris Sherman, Josep M. Llovet, Michel Beaugrand, Riccardo ... Journal of Hepatology, 421-430, 2001 | 5157 | 2001 |
| EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma European Association For The Study Of The Liver Journal of hepatology 56 (4), 908-943, 2012 | 4727 | 2012 |
| Prognosis of hepatocellular carcinoma: the BCLC staging classification JM Llovet, C Brú, J Bruix Seminars in liver disease 19 (03), 329-338, 1999 | 4464 | 1999 |
| Modified RECIST (mRECIST) assessment for hepatocellular carcinoma R Lencioni, JM Llovet Seminars in liver disease 30 (01), 052-060, 2010 | 4129 | 2010 |
| Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial JM Llovet, MI Real, X Montaña, R Planas, S Coll, J Aponte, C Ayuso, ... The Lancet 359 (9319), 1734-1739, 2002 | 3852 | 2002 |
| Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival JM Llovet, J Bruix Hepatology 37 (2), 429-442, 2003 | 3795 | 2003 |
| Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial J Bruix, S Qin, P Merle, A Granito, YH Huang, G Bodoky, M Pracht, ... The Lancet 389 (10064), 56-66, 2017 | 3467 | 2017 |
| Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis V Mazzaferro, JM Llovet, R Miceli, S Bhoori, M Schiavo, L Mariani, ... The lancet oncology 10 (1), 35-43, 2009 | 2160 | 2009 |
| Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation JM Llovet, J Fuster, J Bruix Hepatology 30 (6), 1434-1440, 1999 | 2049 | 1999 |
| Design and endpoints of clinical trials in hepatocellular carcinoma JM Llovet, AM Di Bisceglie, J Bruix, BS Kramer, R Lencioni, AX Zhu, ... Journal of the National Cancer Institute 100 (10), 698-711, 2008 | 2041 | 2008 |
| Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling SM Wilhelm, L Adnane, P Newell, A Villanueva, JM Llovet, M Lynch Molecular cancer therapeutics 7 (10), 3129-3140, 2008 | 1646 | 2008 |
| Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets K Schulze, S Imbeaud, E Letouzé, LB Alexandrov, J Calderaro, ... Nature genetics 47 (5), 505-511, 2015 | 1641 | 2015 |
| EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma JM Llovet (EASL), M Ducreux, R Lencioni, AMD Bisceglie, PR Galle, ... Journal of hepatology 56 (4), 908-943, 2012 | 1570 | 2012 |
| Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma J Bridgewater, PR Galle, SA Khan, JM Llovet, JW Park, T Patel, TM Pawlik, ... Journal of hepatology 60 (6), 1268-1289, 2014 | 1562 | 2014 |
| Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model X Forns, S Ampurdanes, JM Llovet, J Aponte, L Quintó, E Martınez-Bauer, ... Hepatology 36 (4), 986-992, 2002 | 1531 | 2002 |
| Molecular therapies and precision medicine for hepatocellular carcinoma JM Llovet, R Montal, D Sia, RS Finn Nature reviews Clinical oncology 15 (10), 599-616, 2018 | 1525 | 2018 |
| Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo … AX Zhu, YK Kang, CJ Yen, RS Finn, PR Galle, JM Llovet, E Assenat, ... The lancet oncology 20 (2), 282-296, 2019 | 1481 | 2019 |
